Octreotide's Role in the Management of Sulfonylurea-Induced Hypoglycemia

Journal of Medical Toxicology

Volumn 6, Issue 2, 2010, Pages 199-206

  Dougherty, Patrick P ^a,b   Klein Schwartz, Wendy ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Maryland Poison Center   (United States)

Author keywords

Antidote; Octreotide; Overdose; Poisoning; Sulfonylurea

Indexed keywords

ACTIVATED CARBON; ANTIDOTE; CHOLECYSTOKININ; DIAZOXIDE; GASTRIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON; GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; PLACEBO; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR 1;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; BINDING AFFINITY; BONE NECROSIS; BRADYCARDIA; CARBOHYDRATE INTAKE; CLINICAL TRIAL; DIARRHEA; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTOXICATION; DRUG OVERDOSE; FLATULENCE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; INFORMATION RETRIEVAL; INJECTION SITE PAIN; INSULIN RELEASE; MEDICATION ERROR; MEDLINE; METABOLIC ACIDOSIS; NAUSEA; NECROTIZING ENTEROCOLITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT MONITORING; QT PROLONGATION; RECEPTOR BINDING; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE;

ANIMALS; DIAZOXIDE; DIURETICS; GASTROINTESTINAL AGENTS; GLUCAGON; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; OCTREOTIDE; SULFONYLUREA COMPOUNDS;

EID: 77956190323     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-010-0064-z     Document Type: Review

References (34)

1. Winer N, Sowers JR (2004) Epidemiology of diabetes. J Clin Pharmacol 44(4): 397-405. doi: 10. 1177/0091270004263017.
2. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE (2008) 2007 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual report. Clin Toxicol 46(10): 927-1057. doi: 10. 1080/15563650802559632.
3. Szlatenyi CS, Capes DF, Wang RY (1998) Delayed hypoglycemia in a child after ingestion of a single glipizide tablet. Ann Emerg Med 31(6): 773-776. doi: 10. 1016/S0196-0644(98)70240-9.
4. Quadrani DA, Spiller HA, Widder P (1996) Five year retrospective evaluation of sulfonylurea ingestion in children. Clin Toxicol 34(3): 267-270.
5. Spiller HA, Villalobos D, Krenzelok EP, Anderson BD, Gorman SE, Rose SR, Fenn J, Anderson DL, Muir SC, Rodgers GC (1997) Prospective multicenter study of sulfonylurea ingestion in children. J Pediatr 131: 141-146. doi: 10. 1016/S0022-3476(97)70138-0.
6. Little GL, Boniface KS (2005) Are one or two dangerous? Sulfonylurea exposure in toddlers. J Emerg Med 28(3): 305-310. doi: 10. 1016/j. jemermed. 2004. 09. 012.
7. Coates JR, Robbins JJ (1959) Severe hypoglycemic shock due to chlorpropamide. J Am Med Assoc 170(8): 941-942.
8. McKendry JBR (1957) Fatal hypoglycemic coma from the use of tolbutamide (Orinase). Can Med Assoc J 76: 572-573.
9. Mullins ME, Warden CR, Horowitz BZ (1999) Delayed hypoglycemia after ingestion of a single glipizide tablet. Ann Emerg Med 33(1): 129-130. doi: 10. 1016/S0196-0644(99)70437-3.
10. Polonsky KS, Semenkovich CF (2001) The pancreatic β cell heats up: UCP2 and insulin secretion in diabetes. Cell 105(6): 705-707. doi: 10. 1016/S0092-8674(01)00389-0.
11. Yan FF, Casey J, Shyng SL (2006) Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex. J Biol Chem 281(44): 33403-33413. doi: 10. 1074/jbc. M605195200.
12. Cheng AY, Fantus IG (2005) Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172(2): 213-226. doi: 10. 1503/cmaj. 1031414.
13. Kivisto KT, Neuvonen PJ (1990) The effect of cholestyramine and activated charcoal on glipizide absorption. Br J Clin Pharmacol 30: 733-736.
14. Rowden AK, Fasano CJ (2007) Emergency management of oral hypoglycemic drug toxicity. Emerg Med Clin North Am 25: 347-356. doi: 10. 1016/j. emc. 2007. 02. 010.
15. Fleseriu M, Skugor M, Chinnappa P, Siraj ES (2006) Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr Pract 12(6): 635-640.
16. Thoma ME, Glauser J (1996) Persistent hypoglycemia and hyperinsulinemia: caution in using glucagon. Am J Emerg Med 14: 99-101. doi: 10. 1016/S0735-6757(96)90029-7.
17. Altszuler N, Hampshire J, Moraru E (1977) On the mechanism of diazoxide-induced hyperglycemia. Diabetes 26: 931-935. doi: 10. 2337/diabetes. 26. 10. 931.
18. US Food and Drug Administration (2009) Drugs at FDA. Silver Spring: US Food and Drug Administration, Available from: http://www. accessdata. fda. gov/scripts/cder/drugsatfda/index. cfm.
19. Novartis Pharma (2008) Product information: Sandostatin (octreotide acetate). Novartis Pharma, Basel.
20. Jenkins SA, Taylor BA, Nott DM, Ellenbogen S, Haggie J, Shields R (1992) Management of massive upper gastrointestinal haemorrhage from multiple sites of peptic ulceration with somatostatin and octreotide - a report of five cases. Gut 33: 404-407. doi: 10. 1136/gut. 33. 3. 404.
21. Braatvedt GD (1997) Octreotide for the treatment of sulphonylurea induced hypoglycemia in type 2 diabetes. NZ Med J 110: 189-190.
22. Green RS, Palatnick W (2003) Effectiveness of octreotide in a case of refractory sulfonylurea-induced hypoglycemia. J Emerg Med 25(3): 283-287. doi: 10. 1016/S0736-4679(03)00204-X.
23. Carr R, Zed PJ (2002) Octreotide for sulfonylurea-induced hypoglycemia following overdose. Ann Pharmacother 36: 1727-1732. doi: 10. 1345/aph. 1C076.
24. Soderstrom J, Murray L, Daly FFS, Little M (2006) Toxicology case of the month: oral hypoglycaemic overdose. Emerg Med J 23: 565-567. doi: 10. 1136/emj. 2006. 034868.
25. Crawford BAL, Perera C (2004) Octreotide treatment for sulfonylurea-induced hypoglycemia. Med J Aust 180(10): 540-541.
26. Rath S, Naor B-Z, Anderson K, Fahy R, Robeby R (2008) Octreotide in children with hypoglycemia due to sulfonylurea ingestion. J Paediatr Child Health 44: 383-384. doi: 10. 1111/j. 1440-1754. 2008. 01339. x.
27. McLaughlin SA, Crandall CS, McKinney PE (2000) Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med 36(2): 133-138. doi: 10. 1067/mem. 2000. 108183.
28. Kutz K, Neusch E, Rosenthalter J (1986) Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 21: 65-72. doi: 10. 3109/00365528609087433.
29. Chanson P, Timsit J, Harris AG (1993) Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumors. Clin Pharmacokinet 25: 375-391.
30. Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS (1993) Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdose. J Clin Endocrinol Metab 76(3): 752-756. doi: 10. 1210/jc. 76. 3. 752.
31. US Food and Drug Administration, Center for Drug Evaluation and Research (2008) Update on Pediatric Postmarketing Adverse Events. Silver Spring: US Food and Drug Administration. Available from: http://www. fda. gov/ohrms/dockets/ac/08/briefing/2008-4399b1-45%20(Sandostatin%20(octreotide)%20Safety%20Review%202008). pdf.
32. Nzerue CM, Thomas J, Volcy J, Edeki T (2003) Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure. Int J Artif Organs 26(1): 86-89.
33. Gul M, Cander B, Girisgin S, Ayan M, Kocak S, Unlu A (2006) The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose. Adv Ther 23(6): 878-884. doi: 10. 1007/BF02850209.
34. Fasano CJ, O'Malley G, Dominici P, Aguilera E, Latta DR (2008) Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 51(4): 400-406. doi: 10. 1016/j. annemergmed. 2007. 06. 493.